{"nctId":"NCT02914509","briefTitle":"Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT","startDateStruct":{"date":"2016-11-07","type":"ACTUAL"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"count":565,"armGroups":[{"label":"OTX-TP (sustained release travoprost) Intracanalicular Depot","type":"EXPERIMENTAL","interventionNames":["Drug: Travoprost"]},{"label":"PV (Placebo Vehicle) Intracanalicular Depot","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Vehicle"]}],"interventions":[{"name":"Travoprost","otherNames":[]},{"name":"Placebo Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession\n* IOP is currently controlled as assessed by the Investigator\n\nExclusion Criteria:\n\n* Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured using a standard punctum gauge\n* A history of an inadequate response or no response to topical prostaglandin\n* Known or suspected allergy and/or hypersensitivity to travoprost or any prostaglandin, fluorescein, or to any component of the study products","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean IOP","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"0.2"},{"groupId":"OG001","value":"22.9","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"0.2"},{"groupId":"OG001","value":"21.9","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"0.2"},{"groupId":"OG001","value":"21.5","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Mean IOP","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":"0.2"},{"groupId":"OG001","value":"26.9","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":"0.2"},{"groupId":"OG001","value":"25","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"0.2"},{"groupId":"OG001","value":"24.6","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Mean IOP","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":"0.2"},{"groupId":"OG001","value":"23.2","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":"0.2"},{"groupId":"OG001","value":"22.5","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"0.2"},{"groupId":"OG001","value":"22.1","spread":"0.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Serious Adverse Events","description":"Number of Participants with Serious Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":348},"commonTop":["Adverse Event"]}}}